Manage your glucose levels with a smarter CGM (Continuous Glucose Monitoring) system, powered by Guardian™ Sensor 3.
Medtronic is the only company that offers standalone CGM and sensor-integrated pump therapy, which streamlines the process for optimal customer experience. Other CGM companies do not offer an integrated system, requiring an insulin pump from a different company.
Guardian™ Sensor 3, our most advanced sensor, provides an option that fits every lifestyle.
Integrated with our latest advancement in insulin pump therapy, the Guardian™ Sensor 3 enables different levels of automation that fit your lifestyle.
Only Guardian™ Connect CGM powered by Guardian™ Sensor 3 works with the Sugar.IQ™ personal diabetes assistant, which supercharges your understanding of daily glucose patterns and the factors affecting them.∆
A web-based program that collects information directly from your Medtronic diabetes management system. It allows you to generate reports that can be used during your doctor’s visits and to monitor your own progress.
Sage is a professional athlete who is striving to represent the USA at the 2020 Olympics. Sage is constantly traveling around the world competing in two specific water sports: kayaking and canoeing.†† With Sage’s hectic work, travel, and competition schedule, it is critical that she uses a continuous glucose monitor that helps her stay in range. Sage transitioned to the Guardian™ Sensor 3 earlier this year and has been amazed by the experience and results.
The Guardian™ Sensor 3 is the only CGM sensor FDA approved*** to be worn on either the abdomen or on the back of the arm.‡
* Refers to Auto Mode. Some user interaction required. Individual results may vary.
** Data on file.
*** The Guardian™ Connect system is indicated for ages 14 to 75. The MiniMed™ 670G system is indicated for ages 7 to 75. The MiniMed™ 630G system is indicated for 14 years of age and older.
‡ Arm indication approved for ages 14-75.
† dQ&A Diabetes Educator Perspectives Survey, Q3 2015. 428 total respondents. When compared with other software that downloads both insulin pump and continuous glucose monitoring data, CareLink is the #1 preferred software.
∆ The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.
†† At the time of manufacture and when the reservoir and tubing are properly inserted, the pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours.
1 MiniMed™ 670G System SSED. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160017. Accessed July 31, 2018. Arm insertion, 3-4 calibrations per day.
Important Safety Information: Guardian™ Connect CGM System
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and http://www.medtronicdiabetes.com/importantsafetyinformation.
For proper instructions on inserting the Guardian™ sensor 3, visit the support webpage for inserting your sensor.
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Important Safety Information: MiniMed™ 630G System
The MiniMed™ 630G system with SmartGuard™ technology requires a prescription. It is intended for continuous delivery of basal insulin and administration of insulin boluses for the management of diabetes mellitus in persons 14 years of age or older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The SmartGuard™ feature allows one to program the pump to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value. The MiniMed™ 630G system is not intended to be used directly for making therapy adjustments or preventing or treating hypoglycemia. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare professional. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter (BGM). A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day, or who are unwilling or unable to maintain contact with their healthcare professional, or whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use U100 rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard™ Suspend on low feature, it is important to read the SmartGuard™ Suspend on low information in the Getting Started Guide and the MiniMed™ 630G System User Guide and discuss proper use of the SmartGuard™ Suspend on low feature with your healthcare provider.
Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. Please visit www.medtronicdiabetes.com/importantsafetyinformation for more details.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
© Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
AT
AU
BE
BG
CA
CH
CN
CZ
DE
DK
ES
EU
FI
FR
GR
HU
IE
IN
IT
JP
NL
NO
PL
PT
RU
SE
UK
ZA
Alert: Product and Safety Notice
